EP4431512A1 — Novel dual nk-1/nk-3 receptor antagonists
Assigned to Bayer Consumer Care AG · Expires 2024-09-18 · 2y expired
What this patent protects
The present invention relates 2-(3,5-dimethylphenyl)-N-[4-(4-fluorophenyl)-3-pyridyl]-N,2-dimethyl-propanamide compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combin…
USPTO Abstract
The present invention relates 2-(3,5-dimethylphenyl)-N-[4-(4-fluorophenyl)-3-pyridyl]-N,2-dimethyl-propanamide compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of sex-hormone dependent diseases, as a sole agent or in combination with other active ingredients.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.